Exploring therapeutic strategies for C3 Glomerulonephritis (C3G)
C3 glomerulopathy (C3G) is a rare, pesky kidney illness that affects approximately 2-3 folks in every million. This condition results in the accumulation of protein deposits in the kidney's filtering tissues, which, over time, leads to impaired kidney function and potentially kidney failure.
While there's no cure for C3G at the moment, the focus lies in strategies that support kidney health and suppress immune system activity. Traditional treatments often involve systemic suppressors to maintain kidney function, and new therapies are under development that target proteins responsible for disease activity.
Origins of C3G
C3G arises when parts of the immune system go haywire. Certain genes create proteins that monitor the body’s complement system, a vital aspect of the immune system. Genetic modifications to these proteins result in C3G.
Usually, these proteins remain dormant until they encounter potential threats like bacteria or viruses. However, in C3G, these proteins become hyperactive, causing an overproduction of C3 protein. Parts of the C3 protein form deposits within the kidney, particularly targeting the glomeruli, the blood vessels responsible for filtering waste from the blood. The accumulation of C3 deposits causes progressive damage to the glomeruli, reducing the kidneys' ability to filter toxins effectively.
In addition to genetic mutations, the majority of C3G patients carry antibodies that disrupt the regular operation of the complement system. Although genetic links between family members with the condition have been observed, experts believe that the genetic changes in C3G are not solely inherited.
Treatments for C3G can't reverse or prevent the disease; instead, their goal is to slow down the damage to the kidneys. Current treatment guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) organization suggest supportive measures to slow and prevent kidney damage as kidney function declines. Immunosuppressive therapies may also be recommended for individuals with declining kidney function for at least 6 months, or those exhibiting other markers of C3G progression, such as increased levels of protein in the urine.
Conventional Medicines
- ACE inhibitors and ARBs: These medications help lower blood pressure and prevent proteinuria, the leakage of the protein albumin through the kidneys’ filters and into the urine.
- Mycophenolate mofetil (MMF) and glucocorticoids: These immune-suppressing medications are recommended for individuals with C3G once they have experienced declining kidney function for at least 6 months or show signs of C3G progression.
- Complement inhibitors: These medications, such as eculizumab and ravulizumab, stop the activity of the complement system. A doctor may suggest these medications if traditional immunosuppressant medications are ineffective. The use of eculizumab has yielded mixed results.
Dietary Factors
Maintaining a diet that reduces the burden on the kidneys can help individuals with C3G. This might involve reducing sodium, potassium, and phosphorus, maintaining a balance between protein and healthy fats, and balancing fluid intake. Working with a dietitian can help create a diet plan that provides kidney support while still ensuring adequate nutrition.
Future Treatments
Recent and upcoming treatments focus on targeting specific proteins within the complement system to address the underlying causes of C3G. Iptacopan, the first approved treatment for adults with C3G, targets factor B in the alternative complement pathway.
Other treatments currently in various stages of clinical trials include pegcetacoplan, ARO-C3, danicopan, avacopan, KP104, and narsoplimab. Each of these emerging treatments aims to disrupt the complement system at various points, potentially offering new therapeutic options for managing C3G by addressing its root causes.
- C3 glomerulopathy (C3G) is an uncategorized kidney disease that affects approximately 2-3 individuals in every million, characterized by protein deposits in the kidney's filtering tissues due to glomerulopathy.
- The origins of C3G can be traced to malfunctions within the immune system, where genetic modifications to certain proteins that monitor the body's complement system lead to C3G.
- In addition to genetic mutations, C3G patients usually carry antibodies that disrupt the regular operation of the complement system, and while some genetic links between family members with the condition have been observed, genetic changes in C3G are not solely inherited.
- Treatments for C3G aim to slow down the damage to the kidneys rather than reversing or preventing the disease, with current guidelines suggesting supportive measures such as diet, ACE inhibitors, ARBs, Mycophenolate mofetil (MMF), glucocorticoids, and complement inhibitors to maintain kidney function.
- Scientists and medical professionals are developing new therapies for chronic kidney diseases like C3G that target specific proteins within the complement system, including Iptacopan, pegcetacoplan, ARO-C3, danicopan, avacopan, KP104, and narsoplimab.
- Adhering to a proper diet is crucial for individuals with C3G, as maintaining a diet that reduces the burden on the kidneys can help slow down the progression of the disease and support kidney health.
- Chronic-kidney-disease management encompasses not only therapies and treatments but also health-and-wellness factors like diet, lifestyle changes, and potentially neurological-disorders complications, as chronic-diseases often present interconnected medical-conditions.
){kind=link}